For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Scope of the Report:
The classification of Hydroxycarbamide includes capsule and tablet, and the proportion of capsule in 2016 is about 63%, and the proportion is in decreasing trend from 2012 to 2016.
Hydroxycarbamide is widely used for sickle cell disease, cancer and other disease. The most proportion of Hydroxycarbamide is used for sickle cell disease, and the proportion in 2016 is 45%.
Asia Pacific is the largest supplier of Hydroxycarbamide, with a production market share nearly 59% in 2016.
Middle East and Africa is the largest consumption place, with a consumption market share nearly 36% in 2016. Following Middle East and Africa, Asia Pacific is the second largest consumption place with the consumption market share of 20%.
Market competition is not intense. Bristol Myers Squibb, Taj Pharma, Beijing Jialin Pharma, Qilu Pharmaceutical, Teva Pharma, Cipla, Zydus Cadila, United Biotech, Par Pharma, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The worldwide market for Hydroxycarbamide is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Hydroxycarbamide in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Bristol Myers Squibb
- Taj Pharma
- Beijing Jialin Pharma
- Qilu Pharmaceutical
- Teva Pharma
- Cipla
- Zydus Cadila
- United Biotech
- Par Pharma
- Khandelwal Laboratories
- Alkem (Cytomed)
- Samarth Pharma
- VHB Life Sciences
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Capsule
- Tablet
Market Segment by Applications, can be divided into
- Sickle Cell Disease
- Cancer
- Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hydroxycarbamide product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hydroxycarbamide, with price, sales, revenue and global market share of Hydroxycarbamide in 2017 and 2018.
Chapter 3, the Hydroxycarbamide competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hydroxycarbamide breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Hydroxycarbamide market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Hydroxycarbamide sales channel, distributors, customers, research findings and conclusion, appendix and data source.